By analyzing data from 22 RCTs and three observational cohort studies, we established a robust foundation for understanding the cardiovascular benefits of these medications. Our systematic review highlights the promise of SGLT-2 inhibitors for improving cardiovascular health in T2DM patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.